AcuraStem Secures $7 Million in Funding Support from NIH and DOD to Accelerate Therapies for ALS and FTD

Posted on by

AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trials PASADENA, Calif., Jan. 30, 2024 /PRNewswire/ — AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS),…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.